Relay Therapeutics ( (RLAY) ) just unveiled an announcement.
Relay Therapeutics has revealed promising interim clinical data for RLY-2608, a novel treatment for PI3Kα-mutated, HR+, HER2- advanced breast cancer. The drug, an allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, showed a median progression-free survival of 9.2 months in heavily pre-treated patients. With favorable tolerability and significant tumor reduction observed, the data support the planned initiation of a pivotal study in 2025. Relay Therapeutics is also advancing with triplet regimens, including one with Pfizer’s atirmociclib, aiming for global commercialization partnerships to focus on their portfolio.
Learn more about RLAY stock on TipRanks’ Stock Analysis page.
